



Digital Assets & Risk Management

23 June 2022



Marcello Pizzichetta
Director, Enterprise Risk Management

Legal Notice


The information provided in this document is provided “as is” without warranty of any kind; either express or implied, and is intended for informational purposes only. The information contained herein is subject to change at any time without notice.

In no event shall CSL Limited be liable for any direct, indirect, special or consequential damages or any damages whatsoever resulting from loss of use, data, or profits arising out of or in connection with the use of this information. All rights reserved.
All trademarks mentioned herein belong to their respective owners.

Content



Who We Are



Assets & Risks Evolution



Risk Management in Digital Era



Q&A

Who We Are

CSL is a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives.



Cheryl Blackwell Johnson
Living with HAE

CSL at a Glance

35+ 
Countries of operations
around the world


US\$10.3 
billion in annual revenue

US\$4.1 
billion in R&D investments in the last
5 years to advance product pipeline

25,000+ 
employees around the world

1,700 
R&D employees

300+ 
Plasma collection centres across
China, Europe and North America



Immunology

Our world-leading immunoglobulin franchise is the cornerstone of the immunology therapeutic area.

Haematology

Focused on maximising the value and performance of our existing coagulation portfolio, developing new therapies, and identifying transformational treatments to increase quality of life and help patients realise a life full of potential.

Cardiovascular and Metabolic

Focused on improving and extending the lives of patients with cardiovascular disease (CVD) and diabetes.

Respiratory

Respiratory diseases impose an enormous burden on patients and society and are a leading cause of death and disability worldwide.


Transplant

While advances in transplantation techniques and therapies have markedly improved short-term patient survival, transplant rejection remains one of the greatest limitations to long-term graft and patient survival for both solid organ and haematopoietic stem cell transplant recipients.


Influenza Vaccines

Egg-based and cell-based products, seasonal, pre-pandemic and pandemic influenza vaccines.

Our Locations




Our 2030 Strategy



Content



CSL Introduction



Assets & Risks Evolution




Risk Management in Digital Era




Q&A

Assets Evolution



Risks Evolution

*Organizations rate cyber vulnerability (96%) and ransomware (88%) most important risks




New Opportunities

* Gartner – Top 2022 Risk Report

Content



CSL Introduction



Assets & Risks Evolution




Risk Management in Digital Era



Q&A

Risk Management in Digital Era



Sample Global/Corporate:

- Geopolitical Uncertainties
- Reputation risks
- ESG/Business Sustainability

Sample IT, Security, Supply:

- Cybersecurity attacks
- Supply chain
- Third parties
- IP protection

Sample Operational:


- Facility and/or infrastructure integrity
- Workforce health and safety
- Talent Market
- Energy costs

It is time for new opportunities and risk management model

Content



CSL Introduction



Assets & Risks Evolution



Risk Management in Digital Era



Q&A

CSL has earned a reputation as a passionate, responsible company driven to care for patients and deliver on its commitments.



Logan Carty
Living with
Hemophilia B